SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is trending as investors monitor the token's infrastructure role in major institutional tokenization initiatives and anticipation surrounding the Clarity Act. Community sentiment remains polarized, with some bullish on the long-term utility of the oracle network while others express frustration over extended periods of stagnant price performance.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Internet Computer (ICP) is currently trending as investors focus on its shift toward enterprise-grade utility, specifically highlighting its decentralized sovereign cloud infrastructure and AI integration capabilities. Community discussion centers on long-term accumulation strategies, with many bulls pointing to upcoming tokenomics improvements and real-world adoption as potential catalysts to decouple the asset from broader market volatility.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is experiencing significant market interest driven by anticipation of upcoming altcoin season and potential supply shocks from institutional staking and token unlock cycles. The community is actively debating the project's long-term potential, with bulls pointing to strong network activity and infrastructure developments while bears remain focused on past technical outages and volatility.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is trending as investors debate the potential value of its private technology portfolio, particularly regarding its exposure to high-profile IPO candidates like Anthropic and OpenAI. The community is focused on the lack of transparency surrounding the fund's net asset value (NAV) and the impact of recent share offerings, with many questioning why the stock price has remained under pressure despite the positive performance of its underlying holdings like SpaceX.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is trending as investors digest a mix of strong fundamentals, including robust revenue growth and active share buybacks, alongside ongoing concerns regarding short-seller litigation and legal uncertainty. The community is actively debating the stock's long-term valuation, with many bullish investors highlighting the company's high-margin flagship product, ASCENIV, as a primary catalyst for potential future appreciation.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is gaining momentum as investors rotate back into cybersecurity, with the community closely tracking its upcoming earnings and long-term positioning in the AI-driven data resilience space. Sentiment is buoyed by strong institutional activity and a growing thesis that AI workloads necessitate Rubrik's specific recovery capabilities.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is facing intense scrutiny and bearish sentiment as investors debate its long-term viability, with many pointing to the project's quiet communication and the emergence of Janction as a sign of potential abandonment. Despite vocal community skepticism regarding the token's utility and performance, some investors are leveraging current price levels to dollar-cost average, banking on future ecosystem integration and potential regulatory tailwinds in Japan.

Tidal Trust II - Defiance Daily Target 2X Short MU ETF

MUZ is trending as investors actively debate the sustainability of the current AI-driven memory cycle, with many using the leveraged short ETF to hedge against potential pullbacks or bet on a correction. The conversation is heavily focused on broader sector headwinds, including intensifying competition from Chinese manufacturers, ongoing legal challenges regarding patent disputes and facility expansion permits, and general market skepticism regarding semiconductor valuations.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as investors digest the commercial launch of NEREUS for motion sickness while debating the company's prospects for a potential buyout by major pharmaceutical players like Eli Lilly or Novo Nordisk. Community discussion remains focused on the firm's strategic focus on GLP-1 adjunct treatments and active pipeline developments, even as participants express frustration over persistent price volatility.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is currently generating significant community buzz due to its role in the growing AI and space infrastructure sectors, with participants closely monitoring its upcoming inclusion in the Russell 2000 index and recent defense-related contract news. While bulls remain optimistic about long-term potential for memory-tech adoption and institutional accumulation, investors are actively debating the stock's volatility, high short interest, and the impact of technical chart patterns on price stability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AI, Biotech, And Healthcare Catalysts Drive Momentum

Several emerging public companies are attracting attention as artificial intelligence, healthcare innovation, medical technology, and international commercialization strategies continue converging across the market. From AI-powered drug discovery and regenerative medicine expansion to precision dermatology and medical device innovation, recent developments highlight how smaller companies are positioning themselves around some of the fastest-growing sectors in healthcare and technology. $TGNT, $NXTS, $AZTR, $ADTX, $TNON, $PFE

Technological Innovations to Wage War Against Some of Medicine's Toughest Diseases

The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates. $NTHI, $QURE, $ICCM, $CLPT, $ELTX, $AZTR

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for...

This Nano-Cap Pharma Stock Surged 80% Days After A Listing Warning — What’s Fueling the Rally?

Equity

The stock crossed its 100-DMA for the first time in more than eight months after announcing a private placement to raise over $31 million.

Small Caps Swing Big: Capital Raises Fuel AI, Biotech, and EV Ambitions

A flurry of financings, strategic pivots, and technology-driven initiatives is energizing the small-cap space, as companies tap capital markets to chase growth across AI, biotech, and next-generation transportation. $TGNT, $AZTR, $WNW, $UCAR, $JDZG

Nasdaq, S&P 500 Futures Take A Breather Ahead Of Massive Options Expiry: Why SMCI, NVDA, TSLA, UAMY, IBRX Are Keeping Traders Engaged Today

Data from Stocktwits indicated that retail sentiment remains bearish on SPY and QQQ. 


Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million

Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million Azitra Announces Pricing of Private Placement...

Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement

Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE...

Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders

Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders PR Newswire BRANFORD, Conn., March 5, 2026...

Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates

Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates PR Newswire BRANFORD, Conn., Feb. 27, 2026...

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.

Azitra Inc

Bearish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.1393
Prev Close	$0.14
Open	$0.146
Dividend Yield	0.00%
50-Day Moving Average	$0.1603
Beta	1.34
Avg. Volume	1.31M
PE Ratio	-0.11

52-Week High	$1.40
52-Week Low	$0.10
Market Capitalization	$8.44M
EPS (Annual)	-$2.25
Price to Book	1.15
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info